NFKB1 and myeloid sarcoma: The available biological evidence led us to here focus on a priori selected set of genes, CCL2, NFKB1, MAPK14, TNFRSF1A, CXCL10, on the basis of their involvement in MS risk and in NF-κB signaling pathway.